Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
cancer survivorship
chronic lymphocytic leukaemia
preventive health
registries
skin neoplasms
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
07 Jul 2024
07 Jul 2024
Historique:
received:
15
11
2023
accepted:
26
05
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0-35.3) and 4.6 (95% CI: 3.1-6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Janssen Pharmaceutica
ID : 54179060LYM4008
Informations de copyright
© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [Internet]. Geneva: WHO Press; 2008. Available from URL: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002.
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015; 126: 573–581.
Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N et al. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome. eJHaem 2022; 3: 129–138.
Royle JA, Baade PD, Joske D, Girschik J, Fritschi L. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population‐based study. Br J Cancer 2011; 105: 1076–1081.
National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Internet]; 2023 [cited 2023 Jun 13]. Available from URL: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478.
Hallek M, Cheson BD, Catovsky D, Caligaris‐Cappio F, Dighiero G, Döhner H et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745–2760.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.
Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta‐analysis of cohort studies. Melanoma Res 2016; 26: 188–194.
Australian Institute of Health and Welfare. Cancer in Australia 2021; 2021 [Cited 2022 May 25]; Available from URL: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary.
Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J 2019; 9: 75.
van derStraten L, Levin MD, Dinnessen MAW, Visser O, Posthuma EFM, Doorduijn JK et al. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population‐based study in the Netherlands, 1989‐2019. Blood Cancer J 2023; 13: 15.
Australian Institute of Health and Welfare. Cancer Data in Australia. Australian Government; 2022.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019; 94: 1353–1363.
Mulligan SP, Opat S, Marlton P, Kuss B, Gerungan P, Puig A et al. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. Br J Haematol 2022; 198: 790–793.
Al‐Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM et al. Venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: 6‐year results of the randomized CLL14 study. Hematol Oncol 2023; 41: 58–60.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med 2024; 390: 326–337.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2021; 32: 23–33.
Royal Australian College of General Practitioners. Guidelines for Preventive Activities in General Practice, 9th edn. East Melbourne, Vic.: Royal Australian College of General Practitioners; 2016.
Phillips A. Health System Expenditure on Cancer and Other Neoplasms in Australia, 2015–16. Canberra, ACT: Australian Institute of Health and Welfare; 2021.
Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019; 60: 3204–3213.